Catalyst
Slingshot members are tracking this event:
AbbVie (ABBV) Submits NDA to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 19, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Glecaprevir, Pibrentasvir, Chronic Hepatitis C